Abstract
Preclinical autoimmune rheumatic disease (ARD) can be defined as the presence of abnormalities in immune function and responses in the absence of clinically manifest tissue injury Increasing data support the existence of preclinical phase of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) that can be identified using biomarkers of autoimmunity and inflammation RA and SLE could serve as models for understanding the mechanisms of disease development and, ultimately, prevention of other ARDs that in aggregate affect a substantial portion of the population Understanding the preclinical phases of ARD might enable accurate identification of at-risk individuals and the development of preventive interventions that might modify risk factors or target immune pathways underlying disease Identifying both the overall likelihood of future development of an ARD and the timing of onset of clinically apparent disease will be important for 'personalized' medicine and designing prevention trials A range of studies focused on preclinical ARD are needed to clarify the natural history of ARD, and thus enable the development of screening programmes and early, potentially preventive, interventions

This publication has 187 references indexed in Scilit: